WO2006084141A3 - Suspension formulation of interferon - Google Patents
Suspension formulation of interferon Download PDFInfo
- Publication number
- WO2006084141A3 WO2006084141A3 PCT/US2006/003861 US2006003861W WO2006084141A3 WO 2006084141 A3 WO2006084141 A3 WO 2006084141A3 US 2006003861 W US2006003861 W US 2006003861W WO 2006084141 A3 WO2006084141 A3 WO 2006084141A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- interferon
- suspension formulation
- vehicle
- formulation
- suspension
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0058—Additional features; Implant or prostheses properties not otherwise provided for
- A61F2250/0067—Means for introducing or releasing pharmaceutical products into the body
- A61F2250/0068—Means for introducing or releasing pharmaceutical products into the body the pharmaceutical product being in a reservoir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Dispersion Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65022605P | 2005-02-03 | 2005-02-03 | |
US60/650,226 | 2005-02-03 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2006084141A2 WO2006084141A2 (en) | 2006-08-10 |
WO2006084141A3 true WO2006084141A3 (en) | 2006-09-21 |
WO2006084141A8 WO2006084141A8 (en) | 2006-11-09 |
Family
ID=36587040
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/003861 WO2006084141A2 (en) | 2005-02-03 | 2006-02-03 | Suspension formulation of interferon |
PCT/US2006/003857 WO2006084139A2 (en) | 2005-02-03 | 2006-02-03 | An implantable interferon-containing device |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/003857 WO2006084139A2 (en) | 2005-02-03 | 2006-02-03 | An implantable interferon-containing device |
Country Status (5)
Country | Link |
---|---|
US (2) | US7655254B2 (en) |
EP (2) | EP1877077A2 (en) |
JP (1) | JP2008528698A (en) |
CA (1) | CA2596966A1 (en) |
WO (2) | WO2006084141A2 (en) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040001889A1 (en) | 2002-06-25 | 2004-01-01 | Guohua Chen | Short duration depot formulations |
AU2003299659A1 (en) | 2002-12-13 | 2004-07-09 | Durect Corporation | Oral drug delivery system comprising high viscosity liquid carrier materials |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
JP5285275B2 (en) | 2004-09-17 | 2013-09-11 | デュレクト コーポレーション | Controlled delivery system |
US20060141040A1 (en) * | 2004-12-23 | 2006-06-29 | Guohua Chen | Injectable non-aqueous suspension |
US7655254B2 (en) | 2005-02-03 | 2010-02-02 | Intarcia Therapeutics, Inc. | Implantable device for continuous delivery of interferon |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US20070027105A1 (en) | 2005-07-26 | 2007-02-01 | Alza Corporation | Peroxide removal from drug delivery vehicle |
ES2351527T3 (en) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | TWO-PIECE FLOW MODULATOR WITH INTERNAL DUCT FOR AN OSMOTIC ADMINISTRATION SYSTEM. |
EP2359808B1 (en) | 2006-08-09 | 2013-05-22 | Intarcia Therapeutics, Inc | Osmotic delivery systems and piston assemblies |
AU2007325918B2 (en) | 2006-11-03 | 2013-10-17 | Durect Corporation | Transdermal delivery systems comprising bupivacaine |
US8182890B2 (en) * | 2007-01-19 | 2012-05-22 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
US8814930B2 (en) * | 2007-01-19 | 2014-08-26 | Elixir Medical Corporation | Biodegradable endoprosthesis and methods for their fabrication |
US20130150943A1 (en) | 2007-01-19 | 2013-06-13 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
EP2157967B1 (en) | 2007-04-23 | 2013-01-16 | Intarcia Therapeutics, Inc | Suspension formulations of insulinotropic peptides and uses thereof |
JP2011506318A (en) | 2007-12-06 | 2011-03-03 | デュレクト コーポレーション | Oral pharmaceutical formulation |
CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
MX2011003833A (en) * | 2008-10-15 | 2011-06-20 | Intarcia Therapeutics Inc | Highly concentrated drug particles, formulations, suspensions and uses thereof. |
US20100260844A1 (en) | 2008-11-03 | 2010-10-14 | Scicinski Jan J | Oral pharmaceutical dosage forms |
WO2010146536A1 (en) * | 2009-06-18 | 2010-12-23 | Koninklijke Philips Electronics N.V. | Suspension of particles with drug |
WO2011007327A2 (en) * | 2009-07-16 | 2011-01-20 | Koninklijke Philips Electronics N.V. | Suspension for therapeutic use and device for delivering said suspension |
EP3323423B1 (en) | 2009-09-28 | 2020-06-17 | Intarcia Therapeutics, Inc | Rapid establishment and/or termination of substantial steady-state drug delivery |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
ES2563737T3 (en) * | 2011-05-20 | 2016-03-16 | Ares Trading S.A. | IFN-beta compositions, preparation methods and uses thereof |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
AU2013201532B2 (en) | 2011-10-21 | 2014-10-02 | Abbvie Ireland Unlimited Company | Methods for treating HCV |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
CH707029B1 (en) | 2011-10-21 | 2015-03-13 | Abbvie Inc | A method of treating HCV comprising at least two direct acting antiviral agents, ribavirin but not interferon. |
EP2782590A4 (en) * | 2011-11-23 | 2016-08-03 | Durect Corp | Radiation-sterilized biodegradable drug delivery compositions |
CA2905131A1 (en) | 2013-03-15 | 2014-09-18 | Durect Corporation | Compositions with a rheological modifier to reduce dissolution variability |
EP3079668A1 (en) | 2013-12-09 | 2016-10-19 | Durect Corporation | Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same |
WO2018048460A1 (en) | 2014-04-21 | 2018-03-15 | Heron Therapeutics, Inc. | A pharmaceutical composition comprising a delivery system, an amide-type local anesthetic, and meloxicam |
CN114886899B (en) | 2014-04-21 | 2024-02-13 | 赫伦治疗有限公司 | Long-acting polymer delivery system |
US9259339B1 (en) | 2014-08-15 | 2016-02-16 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9855156B2 (en) * | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
MA44390A (en) | 2015-06-03 | 2019-01-23 | Intarcia Therapeutics Inc | IMPLANT PLACEMENT AND REMOVAL SYSTEMS |
US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
SG11201810102SA (en) | 2016-05-16 | 2018-12-28 | Intarcia Therapeutics Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
EP3457985B1 (en) | 2016-05-16 | 2021-02-17 | Elixir Medical Corporation | Uncaging stent |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
CN110225762A (en) | 2017-01-03 | 2019-09-10 | 因塔西亚制药公司 | The method of the co-administration of continuous administration and drug including GLP-1 receptor stimulating agent |
KR20220140711A (en) | 2020-01-13 | 2022-10-18 | 듀렉트 코퍼레이션 | Reduced Impurity Sustained Release Drug Delivery Systems and Related Methods |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027963A2 (en) * | 1996-12-20 | 1998-07-02 | Alza Corporation | Gel composition and methods |
WO2000045790A2 (en) * | 1999-02-08 | 2000-08-10 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5219572A (en) * | 1989-03-17 | 1993-06-15 | Pitman-Moore, Inc. | Controlled release delivery device for macromolecular proteins |
US5904935A (en) * | 1995-06-07 | 1999-05-18 | Alza Corporation | Peptide/protein suspending formulations |
US6132420A (en) * | 1996-02-02 | 2000-10-17 | Alza Corporation | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
PT1238658E (en) * | 1996-02-02 | 2005-04-29 | Alza Corp | CONTROLLED ADMINISTRATION OF AN ACTIVE AGENT THAT USES AN IMPLANTABLE SYSTEM |
US5932547A (en) * | 1996-07-03 | 1999-08-03 | Alza Corporation | Non-aqueous polar aprotic peptide formulations |
ZA981610B (en) * | 1997-03-24 | 1999-08-26 | Alza Corp | Self adjustable exit port. |
MY125849A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems |
MY125870A (en) * | 1997-07-25 | 2006-08-30 | Alza Corp | Osmotic delivery system flow modulator apparatus and method |
US6368612B1 (en) * | 1997-12-12 | 2002-04-09 | Biohybrid Technologies Llc | Devices for cloaking transplanted cells |
JP4215188B2 (en) * | 1997-12-22 | 2009-01-28 | インターシア セラピューティクス,インコーポレイティド | Rate-regulating membranes for devices that regulate drug delivery |
EP1041968B1 (en) * | 1997-12-29 | 2004-03-03 | Alza Corporation | Osmotic delivery system with membrane plug retention mechanism |
PT1736145E (en) * | 1997-12-30 | 2012-03-16 | Intarcia Therapeutics Inc | Beneficial agent delivery system with membrane plug |
WO2000029206A1 (en) * | 1998-11-13 | 2000-05-25 | Sensor Technologies Inc. | Monodisperse preparations useful with implanted devices |
DE69906132T2 (en) * | 1998-12-31 | 2003-12-18 | Alza Corp | OSMOTIC ADMINISTRATION SYSTEM WITH SPILLAGE PISTONS |
US6703225B1 (en) * | 1999-01-12 | 2004-03-09 | Sumitomo Pharmaceuticals Company, Limited | Interferon-α |
US7258869B1 (en) * | 1999-02-08 | 2007-08-21 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle |
US20030059376A1 (en) * | 1999-06-04 | 2003-03-27 | Libbey Miles A. | Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same |
WO2001045675A2 (en) * | 1999-12-21 | 2001-06-28 | Alza Corporation | Valve for osmotic devices |
AU5911101A (en) * | 2000-04-19 | 2001-10-30 | Genentech Inc | Sustained release formulations |
US20020197235A1 (en) | 2000-11-03 | 2002-12-26 | Moran Stanford Mark | Method for short-term and long-term drug dosimetry |
US7163688B2 (en) * | 2001-06-22 | 2007-01-16 | Alza Corporation | Osmotic implant with membrane and membrane retention means |
CN1549724A (en) | 2001-07-20 | 2004-11-24 | ����ͨѶ�ɷ�����˾ | Methods of treating liver fibrosis |
DE60239556D1 (en) * | 2001-11-14 | 2011-05-05 | Durect Corp | CATHETERINJICIBLE DEPOT COMPOSITIONS AND THEIR USE |
KR20040065153A (en) * | 2001-11-14 | 2004-07-21 | 알자 코포레이션 | Injectable depot composition |
US20030170289A1 (en) * | 2001-11-14 | 2003-09-11 | Guohua Chen | Injectable depot compositions and uses thereof |
WO2003087335A2 (en) * | 2002-04-11 | 2003-10-23 | Medimmune Vaccines, Inc. | Preservation of bioactive materials by spray drying |
CN1668279A (en) * | 2002-06-17 | 2005-09-14 | 阿尔萨公司 | Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle |
MXPA05000224A (en) * | 2002-06-26 | 2005-06-03 | Alza Corp | Minimally compliant, volume efficient piston for osmotic drug delivery systems. |
US7014636B2 (en) * | 2002-11-21 | 2006-03-21 | Alza Corporation | Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel |
US7731947B2 (en) * | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
US20040224903A1 (en) * | 2002-12-19 | 2004-11-11 | Stephen Berry | Stable, non-aqueous, single-phase gels and formulations thereof for delivery from an implantable device |
JP2006521897A (en) * | 2003-03-31 | 2006-09-28 | アルザ・コーポレーション | Osmotic pump with means for dissipating internal pressure |
US20050175701A1 (en) * | 2004-02-10 | 2005-08-11 | Alza Corporation | Capillary moderator for osmotic delivery system |
US20050266087A1 (en) * | 2004-05-25 | 2005-12-01 | Gunjan Junnarkar | Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium |
US7655254B2 (en) * | 2005-02-03 | 2010-02-02 | Intarcia Therapeutics, Inc. | Implantable device for continuous delivery of interferon |
WO2006083761A2 (en) * | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
US20060216242A1 (en) * | 2005-02-03 | 2006-09-28 | Rohloff Catherine M | Suspending vehicles and pharmaceutical suspensions for drug dosage forms |
US7959938B2 (en) * | 2005-03-15 | 2011-06-14 | Intarcia Therapeutics, Inc. | Polyoxaester suspending vehicles for use with implantable delivery systems |
ES2351527T3 (en) * | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | TWO-PIECE FLOW MODULATOR WITH INTERNAL DUCT FOR AN OSMOTIC ADMINISTRATION SYSTEM. |
-
2006
- 2006-02-03 US US11/347,601 patent/US7655254B2/en active Active
- 2006-02-03 WO PCT/US2006/003861 patent/WO2006084141A2/en active Application Filing
- 2006-02-03 EP EP06720233A patent/EP1877077A2/en not_active Withdrawn
- 2006-02-03 CA CA002596966A patent/CA2596966A1/en not_active Abandoned
- 2006-02-03 US US11/347,109 patent/US20060263433A1/en not_active Abandoned
- 2006-02-03 EP EP11165436A patent/EP2361630A1/en not_active Withdrawn
- 2006-02-03 WO PCT/US2006/003857 patent/WO2006084139A2/en active Application Filing
- 2006-02-03 JP JP2007554243A patent/JP2008528698A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998027963A2 (en) * | 1996-12-20 | 1998-07-02 | Alza Corporation | Gel composition and methods |
WO2000045790A2 (en) * | 1999-02-08 | 2000-08-10 | Alza Corporation | Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles |
WO2004089335A2 (en) * | 2003-03-31 | 2004-10-21 | Alza Corporation | Non-aqueous single phase vehicles and formulations utilizing such vehicles |
Also Published As
Publication number | Publication date |
---|---|
WO2006084139A8 (en) | 2007-12-27 |
US20060251618A1 (en) | 2006-11-09 |
US7655254B2 (en) | 2010-02-02 |
JP2008528698A (en) | 2008-07-31 |
WO2006084139A2 (en) | 2006-08-10 |
US20060263433A1 (en) | 2006-11-23 |
CA2596966A1 (en) | 2006-08-10 |
EP1877077A2 (en) | 2008-01-16 |
WO2006084139A3 (en) | 2006-10-19 |
WO2006084141A8 (en) | 2006-11-09 |
EP2361630A1 (en) | 2011-08-31 |
WO2006084141A2 (en) | 2006-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006084141A8 (en) | Suspension formulation of interferon | |
WO2005115333A3 (en) | A biomolecule-containing formulation of increased stability | |
WO2003080024A3 (en) | Nanoparticulate compositions of map kinase inhibitors | |
WO2007075747A3 (en) | Uv-radiation protectant compositions | |
WO2006034311A3 (en) | Low voltage track and hold circuits | |
DK1443912T3 (en) | Compositions with a combination of immediate and controlled release properties | |
WO2007038220A3 (en) | Organic-inorganic hybrid particle material and polymer compositions containing same | |
CA2326137A1 (en) | Method for stabilizing pharmaceutical compositions by special use of an antioxidant | |
WO2006042132A3 (en) | Microencapsulation of cells in hydrogels using electrostatic potentials | |
WO2006074462A3 (en) | Electrostatic discharge protection for embedded components | |
WO2004071452A3 (en) | Random and non-random alkylene oxide polymer alloy compositions | |
FI932123A0 (en) | Stable, agglomerated water suspension in the form of an oil, polymer based on reducing friction | |
ATE457718T1 (en) | STERILE FILTERED NANOPARTICLE FORMULATIONS OF BUDESONIDE WITH TYLOXAPOL AS SURFACE STABILIZER | |
TW200630422A (en) | Stabilized orange materials containing fillers | |
TW200634181A (en) | Electroplating composition and method | |
SG161203A1 (en) | Nanoparticulate tacrolimus formulations | |
WO2008036423A3 (en) | Formulations for voltage switchable dielectric material having a stepped voltage response and methods for making the same | |
WO2005009375A3 (en) | Small spherical particles of low molecular weight organic molecules and methods of preparation and use thereof | |
WO2007033372A3 (en) | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents | |
EP2437271A3 (en) | Voltage switchable dielectric material having conductive or semi-conductive organic material | |
WO2005111129A3 (en) | Composition comprising polymer and derivatized nanoparticles | |
ATE418147T1 (en) | CONDUCTIVE POLYMER COMPOSITIONS AND ARTICLES CONTAINING SAME | |
WO2004004683A8 (en) | Solid dispersions comprising two different polymer matrixes | |
WO2009052163A3 (en) | Crosslinkable fluoropolymer composition and uses thereof | |
WO2004081122A8 (en) | Anti-statically coated moulded body and method for the production thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 06720237 Country of ref document: EP Kind code of ref document: A2 |